{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:24:36Z","timestamp":1794277476199,"version":"4.9.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zenflow, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01126-3","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:06:24Z","timestamp":1781006784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Zenflow spring system for benign prostatic hyperplasia - 24 month outcomes of the ZEST pilot studies"],"prefix":"10.1038","author":[{"given":"Peter","family":"Gilling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-9597","authenticated-orcid":false,"given":"Paul","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-6669","authenticated-orcid":false,"given":"Kevin","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3120-3406","authenticated-orcid":false,"given":"Edward D.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"P\u00e9rez Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-7783","authenticated-orcid":false,"given":"Dean","family":"Elterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"1126_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474\u20139. https:\/\/doi.org\/10.1016\/s0022-5347(17)49698-4.","journal-title":"J Urol"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","volume":"179","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, Siami P, Barkin J, Dami\u00e3o R, Majo-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179:616\u201321. https:\/\/doi.org\/10.1016\/j.juro.2007.09.084.","journal-title":"J Urol"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","volume":"68","author":"L Cindolo","year":"2015","unstructured":"Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418\u201325. https:\/\/doi.org\/10.1016\/j.eururo.2014.11.006.","journal-title":"Eur Urol"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.juro.2009.01.033","volume":"181","author":"MB Nichol","year":"2009","unstructured":"Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009;181:2214\u201321. https:\/\/doi.org\/10.1016\/j.juro.2009.01.033.","journal-title":"J Urol"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.eururo.2005.12.042","volume":"50","author":"J Rassweiler","year":"2006","unstructured":"Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)\u2013incidence, management, and prevention. Eur Urol. 2006;50:969\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.042.","journal-title":"Eur Urol"},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.colegn.2015.07.001","volume":"24","author":"S Kusljic","year":"2017","unstructured":"Kusljic S, Aneja J, Manias E. Incidence of complications in men undergoing transurethral resection of the prostate. Collegian. 2017;24:3\u20139. https:\/\/doi.org\/10.1016\/j.colegn.2015.07.001.","journal-title":"Collegian"},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.euf.2024.12.008","volume":"11","author":"D Elterman","year":"2025","unstructured":"Elterman D, Kaplan SA. Reimagining Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Treatment: A New Approach to First-line Interventional Therapy. Eur Urol Focus. 2025;11:508\u201310. https:\/\/doi.org\/10.1016\/j.euf.2024.12.008.","journal-title":"Eur Urol Focus"},{"key":"1126_CR8","first-page":"10580","volume":"28","author":"DS Elterman","year":"2021","unstructured":"Elterman DS, Zorn KC, Chughtai B, Bhojani N. Is it time to offer True Minimally Invasive Treatments (TMIST) for BPH? - A review of office-based therapies and introduction of a new technology category. Can J Urol. 2021;28:10580\u20133.","journal-title":"Can J Urol"},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.juro.2012.08.257","volume":"189","author":"MJ Barry","year":"2013","unstructured":"Barry MJ, Cantor A, Roehrborn CG. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. J Urol. 2013;189:987\u201392. https:\/\/doi.org\/10.1016\/j.juro.2012.08.257.","journal-title":"J Urol"},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.euf.2025.05.018","volume":"11","author":"S Malde","year":"2025","unstructured":"Malde S, Drake MJ, Tikkinen KAO. Patient Values, Preferences, and Expectations for Managing Symptoms Due to Benign Prostate Obstruction. Eur Urol Focus. 2025;11:568\u201370. https:\/\/doi.org\/10.1016\/j.euf.2025.05.018.","journal-title":"Eur Urol Focus"},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.jsxm.2020.07.006","volume":"17","author":"D Bouhadana","year":"2020","unstructured":"Bouhadana D, Nguyen DD, Zorn KC, Elterman DS, Bhojani N. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. J Sex Med. 2020;17:2108\u201312. https:\/\/doi.org\/10.1016\/j.jsxm.2020.07.006.","journal-title":"J Sex Med"},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.urology.2022.01.012","volume":"164","author":"PJ Huffman","year":"2022","unstructured":"Huffman PJ, Yin E, Cohen AJ. Evaluating Patient Preferences in Benign Prostatic Hyperplasia Treatment Using Conjoint Analysis. Urology. 2022;164:211\u20137. https:\/\/doi.org\/10.1016\/j.urology.2022.01.012.","journal-title":"Urology"},{"key":"1126_CR13","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190:2161\u20137. https:\/\/doi.org\/10.1016\/j.juro.2013.05.116.","journal-title":"J Urol"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","volume":"195","author":"KT McVary","year":"2016","unstructured":"McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2016;195:1529\u201338. https:\/\/doi.org\/10.1016\/j.juro.2015.10.181.","journal-title":"J Urol"},{"key":"1126_CR15","first-page":"7772","volume":"22","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015;22:7772\u201382.","journal-title":"Can J Urol"},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2017.10.023","volume":"111","author":"KT McVary","year":"2018","unstructured":"McVary KT, Roehrborn CG. Three-Year Outcomes of the Prospective, Randomized Controlled Rez\u016bm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Urology. 2018;111:1\u20139. https:\/\/doi.org\/10.1016\/j.urology.2017.10.023.","journal-title":"Urology"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01126-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:37:17Z","timestamp":1789551437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":16,"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01126-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PG, PC, PA, KZ, EDM, WL, LC, HW, RPB, JB, and DE served as principal investigators (PI) on this clinical trial. PG is a study investigator for Procept Biorobotics, Rivermark and Resurge. PC is a consultant and proctor for Teleflex. KZ is a consultant\/advisor for Procept, BSCI, Laborie, and Zenflow. WL is a consultant for Rigicon, Boston Scientific, Medtronic, and Inopase. DE is a consultant\/advisor for Astellas, Boston Scientific, Laborie, Medtronic, Pierre Fabre, Procept BioRobotics, Prodeon, Proverum, Butterfly, and Zenflow.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}